Currently Viewing:
American Society of Clinical Oncology Annual Meeting
Persephone Trial: Cutting Trastuzumab Duration by Half Safer, Efficacious in HER2-Positive Breast Cancer
May 29, 2018
Remote Monitoring Can Reduce Radiation-Related Symptoms in Head and Neck Cancer
May 30, 2018
Despite USPSTF Recommendations, Lung Screening Rates Low Among Heavy Smokers
May 31, 2018
Nelarabine With Chemotherapy Boosted Outcomes in Pediatric and YA Patients With T-Cell Cancers
June 01, 2018
Dr Leonard B. Saltz on Deciding When a Patient Should Receive NGS Testing
June 02, 2018
Promising Early Phase Results With bb2121 CAR T Treatment in Relapsed Refractory Multiple Myeloma
June 02, 2018
Dr Peter Paul Yu Discusses the Impact of Health Information Technology in Oncology
June 02, 2018
Identifying Rational Immunotherapy Combinations for Glioblastoma: A Progress Report
June 02, 2018
Dr James Lin Chen Outlines Information Needs in Era of Precision Medicine
June 02, 2018
Ellen Miller Sonet Highlights Financial Burdens of Patients With Cancer
June 02, 2018
Utilization Management in Oncology: Current Strategies and a Path Forward
June 02, 2018
Immune Checkpoint Inhibitors Improve Outcomes in Mismatch Repair Deficient CRC, but Can Induce irAEs
June 02, 2018
ZUMA-1: Response to Axi-cel at Three Months Prognostic for Remission in B-cell Lymphoma
June 03, 2018
Cetuximab With Chemoradiation Worse Than Chemoradiation Alone in Older Patients With HNSCC
June 03, 2018
Dr Michael Thompson: The Role of Precision Medicine in the Community Setting
June 03, 2018
Dr Victoria Villaflor Outlines Challenges With Pursuing Precision Medicine
June 03, 2018
Clinical Trials: Sharing the Road With Real-World Evidence
June 04, 2018
Phase 3 TAILORx Results Confirm Chemotherapy Unnecessary in 70% of Women With Early-Stage Breast Cancer
June 04, 2018
KEYNOTE-042 Confirms First-Line Pembrolizumab Superior to Chemotherapy in PD-L1–Low Advanced NSCLC
June 04, 2018
Currently Reading
Cemiplimab, in GOG 3016, Looks to Break New Ground for Immunotherapy in Cervical Cancer
June 04, 2018
Opdivo Plus Chemo Boosts Progression-Free Survival 26% Over Chemo Alone in Late-Stage NSCLC
June 04, 2018
Managing Cancer-Related Pain in the Era of the Opioid Crisis
June 06, 2018
Discussing the Cost Burden of Cancer With Patients
June 06, 2018
Study Underscores Value of PROs in Improving Lung Cancer Survival
June 07, 2018

Cemiplimab, in GOG 3016, Looks to Break New Ground for Immunotherapy in Cervical Cancer

Mary Caffrey
Regeneron's Matthew Fury, MD, said the decision to move immediately to a phase 3 trial came after 2 of 3 patients in a phase 1 trial showed durable responses.
Several studies involving immunotherapy to treat cervical cancer have reached phase 2. But a phase 3 trial is under way with cemiplimab, after researchers at Regeneron saw a positive signal in a phase 1 study and opted to move immediately to a randomized clinical trial. GOG 3016, which is now recruiting participants at 53 locations in the United States and internationally, activated in late 2017 to study patients with recurrent and metastatic cervical carcinoma.

While patients with cervical cancer may experience modest survival benefits with initial treatment (with or without bevacizumab), those who have a recurrence after being treated with platinum-based chemotherapy have a median survival of just 7 months, according to the research being presented Monday at the annual meeting of the American Society of Clinical Oncology, held in Chicago, Illinois. But the nature of cervical cancer meant that immunotherapy could be a treatment choice.

“For women with metatstatic cervical cancer who have progressed on first-line therapy, there really has been nothing out there for them,” Matthew Fury, MD, senior director of clinical sciences in oncology for Regeneron, said in an email to The American Journal of Managed Care®. “Because almost all cervical cancers are HPV-associated, the presence of a viral antigen in these tumors creates the potential for robust anti-tumor immune responses and prolonged survival.”

GOG 3016 is a randomized (1:1), open-label trial, that seeks to enroll 436 patients who have previously been treated with platinum-based chemotherapy, will receive either cemiplimab, a human monoclonal anti-programmed death cell-1 therapy, or chemotherapy of the investigator’s choice of several forms of chemotherapy:
  • antifolate: pemetrexed
  • topoisomerase 1 inhibitor: topotecan or irinotecan
  • nucleoside analogue: gemcitabine
  • vinca alkaloid: vinorelbine

Fury said GOG 3016 results from the phase 1 study of cemiplimab showed durable responses in 2 of the 3 cervical cancer patients who were enrolled in the dose escalation portion of the study. “We thought that this was a potentially important efficacy signal in a patient population with unmet need,” Fury said, and the results dovetailed with those being seen with immune checkpoint inhibitors in other virally-associated cancers, like oropharynx cancer and Merkel cell carcinoma.

“These observations suggested to use that cemiplimab has the potential to improve survival in women with advanced cervical cancer who have exhausted the potential for clinical benefit with currently available treatments, and that a phase 3 trial was the way to go,” Fury said.

Similarly, Regeneron moved quickly on an early impressive signal in a patient with advanced cutaneous squamous cell carcinoma, he said.


Tewari KS, Vergote I, Oaknin A, et al. GOG 3016/ENGOT-cx9: an open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator’s choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer. J Clin Oncol 2018;36 (suppl; abstr TPS5600).

Related Articles

Need to Revisit Cervical Cancer Screening Guidelines: JAMA Oncology Study
Pembrolizumab Granted Priority Review for Treatment of Cervical Cancer
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up